View More Recent Stories
-
ImmunityBio (IBRX) Announces Proposed Public Offering of Common Stock
-
ImmunityBio (IBRX) and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment
-
ImmunityBio, Inc. (IBRX) Tops Q3 EPS by 4c
-
ImmunityBio (IBRX) call put ratio 9.6 calls to 1 put with a focus on November 4.5, November 7 and January 10 calls
-
EF Hutton Starts Immunitybio Inc (IBRX) at Buy
-
ImmunityBio (IBRX) Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA and Checkpoint Immunotherapy
